[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:solid-neoplasm":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":313,"states":399},"Solid Neoplasm",1133,1015,[8,16,23,29,35,41,47,53,60,66,73,79,85,91,97,103,110,116,122,128,134,140,146,152,158,164,170,176,182,188,194,200,206,212,218,224,230,236,242,248,254,260,266,272,277,283,289,295,301,307],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06998407","ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and\u002For Endocrine Therapy in Advanced Solid Tumors",[12],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:15:49.658025Z","2026-07-30T01:46:14.469288Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06771219","SLV-154 Treatment of Advanced Cancers",[20],"Phase 1","2026-08-26T02:16:46.147215Z","2026-07-30T01:46:14.467064Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT07460375","A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors",[12],"2026-08-26T02:16:08.402952Z","2026-07-30T01:46:14.433676Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT07414836","A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors",[20],"2026-08-26T02:16:48.735701Z","2026-07-24T01:27:14.896510Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT06234098","Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors",[12],"2026-08-26T02:18:29.369233Z","2026-07-24T01:27:14.872455Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":45,"content_modified":46},"NCT06043713","Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Solid Tumor Cancers With KRAS G12V Mutations",[20],"2026-08-26T02:16:45.157238Z","2026-07-19T19:36:05.129956Z",{"nct_id":48,"title":49,"phases":50,"status":13,"updated_at":51,"content_modified":52},"NCT05875168","First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors",[12],"2026-08-26T02:17:45.190188Z","2026-07-19T19:36:05.118782Z",{"nct_id":54,"title":55,"phases":56,"status":13,"updated_at":58,"content_modified":59},"NCT07505771","A Phase 1 Study of 177Lu-IM-3050 in Participants With Advanced Cancer",[57],"Early Phase 1","2026-08-26T02:16:39.977107Z","2026-07-19T19:36:05.074106Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":64,"content_modified":65},"NCT05687136","Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors",[20],"2026-08-26T02:17:30.145302Z","2026-07-05T05:32:16.811559Z",{"nct_id":67,"title":68,"phases":69,"status":13,"updated_at":71,"content_modified":72},"NCT06630416","Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors",[70],"Phase 2","2026-08-26T02:15:00.557154Z","2026-07-05T05:32:16.766648Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT06678659","A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer",[12],"2026-08-26T02:16:06.684983Z","2026-07-05T05:32:16.765011Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":83,"content_modified":84},"NCT06386146","JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation",[12],"2026-08-26T02:19:02.550788Z","2026-07-05T05:32:16.751547Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":89,"content_modified":90},"NCT06130553","A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced\u002FMetastatic Solid Tumors",[12],"2026-08-26T02:15:45.413021Z","2026-07-05T05:32:16.744919Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":95,"content_modified":96},"NCT05901285","Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors",[20],"2026-08-26T02:19:26.493949Z","2026-07-05T05:32:16.737673Z",{"nct_id":98,"title":99,"phases":100,"status":13,"updated_at":101,"content_modified":102},"NCT06952010","A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors",[20],"2026-08-26T02:16:50.548894Z","2026-07-05T05:32:16.706843Z",{"nct_id":104,"title":105,"phases":106,"status":13,"updated_at":108,"content_modified":109},"NCT07217301","A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer",[107],"Phase 3","2026-08-26T02:15:53.461103Z","2026-07-05T05:32:16.669823Z",{"nct_id":111,"title":112,"phases":113,"status":13,"updated_at":114,"content_modified":115},"NCT07196644","A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan",[70],"2026-08-26T02:17:59.904383Z","2026-07-05T05:32:16.657621Z",{"nct_id":117,"title":118,"phases":119,"status":13,"updated_at":120,"content_modified":121},"NCT05098132","Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers",[12],"2026-08-26T02:18:17.007929Z","2026-07-05T03:45:20.449302Z",{"nct_id":123,"title":124,"phases":125,"status":13,"updated_at":126,"content_modified":127},"NCT07671534","Metronomic Gemcitabine, Mitomycin C, and Thalidomide for Advanced Solid Tumors",[70],"2026-08-26T02:17:10.213717Z","2026-07-05T03:45:20.372930Z",{"nct_id":129,"title":130,"phases":131,"status":13,"updated_at":132,"content_modified":133},"NCT07601243","Study of GS-2426 in Participants With Advanced Solid Tumors",[20],"2026-08-26T02:17:15.156099Z","2026-07-05T03:45:20.254014Z",{"nct_id":135,"title":136,"phases":137,"status":13,"updated_at":138,"content_modified":139},"NCT06414460","Study of ISM3412 in Participants With Locally Advanced\u002FMetastatic Solid Tumors",[12],"2026-08-26T02:16:47.762107Z","2026-06-18T12:24:03.105083Z",{"nct_id":141,"title":142,"phases":143,"status":13,"updated_at":144,"content_modified":145},"NCT03424005","A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer",[12],"2026-08-26T02:15:26.669629Z","2026-06-17T19:21:16.689089Z",{"nct_id":147,"title":148,"phases":149,"status":13,"updated_at":150,"content_modified":151},"NCT05384626","A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)",[12],"2026-08-26T02:15:43.339060Z","2026-06-17T19:21:16.597610Z",{"nct_id":153,"title":154,"phases":155,"status":13,"updated_at":156,"content_modified":157},"NCT06551142","A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)",[20],"2026-08-26T02:16:16.169331Z","2026-06-16T05:54:07.918829Z",{"nct_id":159,"title":160,"phases":161,"status":13,"updated_at":162,"content_modified":163},"NCT05232409","Determine Safety & Recommended Phase 2 Dosing of Zeaxanthin Alone or in Combination w\u002FPembrolizumab in Patients With Metastatic Cancer",[20],"2026-08-26T02:15:47.754948Z","2026-06-06T00:48:49.516212Z",{"nct_id":165,"title":166,"phases":167,"status":13,"updated_at":168,"content_modified":169},"NCT07086768","Dose-Escalation and Dose-Expansion Study of BSI-082 Monotherapy and Combined Therapy in Patients With Advanced or Metastatic Solid Tumors",[20],"2026-08-26T02:18:57.189473Z","2026-06-04T01:30:07.896454Z",{"nct_id":171,"title":172,"phases":173,"status":13,"updated_at":174,"content_modified":175},"NCT07612176","A Phase 1 Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors",[20],"2026-08-26T02:18:23.582895Z","2026-05-29T15:36:40.230934Z",{"nct_id":177,"title":178,"phases":179,"status":13,"updated_at":180,"content_modified":181},"NCT07612189","A Phase 1 Study of NEOK002, an EGFR and MUC1 Targeting Bispecific ADC, in Participants With Select Solid Tumors",[20],"2026-08-26T02:18:42.501841Z","2026-05-29T15:36:40.230911Z",{"nct_id":183,"title":184,"phases":185,"status":13,"updated_at":186,"content_modified":187},"NCT07607678","A Study in People With Advanced Cancer to Test How Well Different Doses of BI 3819026 Are Tolerated When Taken Alone and Together With Ezabenlimab",[20],"2026-08-26T02:19:31.671303Z","2026-05-29T15:36:40.225270Z",{"nct_id":189,"title":190,"phases":191,"status":13,"updated_at":192,"content_modified":193},"NCT07605962","Phase 1\u002F2 Study of UI-102 in Selected Advanced Cancers",[12],"2026-08-26T02:18:07.037408Z","2026-05-29T15:36:40.223624Z",{"nct_id":195,"title":196,"phases":197,"status":13,"updated_at":198,"content_modified":199},"NCT07584226","A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors",[20],"2026-08-26T02:16:52.995882Z","2026-05-29T15:36:40.197011Z",{"nct_id":201,"title":202,"phases":203,"status":13,"updated_at":204,"content_modified":205},"NCT07438782","First Time in Human (FTIH) Study to Investigate the Safety and Preliminary Activity of GSK5533524 Alone or in Combination in Adult Participants With Advanced Solid Tumors",[20],"2026-08-26T02:15:02.712396Z","2026-05-29T15:36:40.188141Z",{"nct_id":207,"title":208,"phases":209,"status":13,"updated_at":210,"content_modified":211},"NCT07387068","Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Advanced Solid Tumors",[20],"2026-08-26T02:16:07.529922Z","2026-05-29T15:36:40.187439Z",{"nct_id":213,"title":214,"phases":215,"status":13,"updated_at":216,"content_modified":217},"NCT06656390","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors",[12],"2026-08-26T02:17:48.768272Z","2026-05-29T15:36:40.169761Z",{"nct_id":219,"title":220,"phases":221,"status":13,"updated_at":222,"content_modified":223},"NCT07286032","A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia",[107],"2026-08-26T02:17:22.949982Z","2026-05-13T02:55:06.684295Z",{"nct_id":225,"title":226,"phases":227,"status":13,"updated_at":228,"content_modified":229},"NCT06819735","Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors",[12],"2026-08-26T02:17:13.277148Z","2026-05-13T02:55:06.581402Z",{"nct_id":231,"title":232,"phases":233,"status":13,"updated_at":234,"content_modified":235},"NCT05898399","Study of ART6043 in Advanced\u002FMetastatic Solid Tumors Patients (POLKA)",[12],"2026-08-26T02:17:32.059863Z","2026-05-13T02:55:06.392298Z",{"nct_id":237,"title":238,"phases":239,"status":13,"updated_at":240,"content_modified":241},"NCT06994806","A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies",[20],"2026-08-26T02:17:39.857430Z","2026-05-05T02:43:29.738362Z",{"nct_id":243,"title":244,"phases":245,"status":13,"updated_at":246,"content_modified":247},"NCT04775485","A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors",[70],"2026-08-26T02:18:45.196599Z","2026-05-05T02:43:29.733815Z",{"nct_id":249,"title":250,"phases":251,"status":13,"updated_at":252,"content_modified":253},"NCT05270213","Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors",[20],"2026-08-26T02:19:27.519777Z","2026-05-05T02:43:29.728001Z",{"nct_id":255,"title":256,"phases":257,"status":13,"updated_at":258,"content_modified":259},"NCT06028074","Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies",[12],"2026-08-26T02:17:20.511551Z","2026-05-05T02:43:29.726158Z",{"nct_id":261,"title":262,"phases":263,"status":13,"updated_at":264,"content_modified":265},"NCT05320588","A Study in Patients With Advanced Cancers",[12],"2026-08-26T02:17:58.890423Z","2026-05-05T02:43:29.723456Z",{"nct_id":267,"title":268,"phases":269,"status":13,"updated_at":270,"content_modified":271},"NCT04485013","TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers",[20],"2026-08-26T02:18:33.598205Z","2026-05-05T02:43:29.711333Z",{"nct_id":273,"title":274,"phases":275,"status":13,"updated_at":264,"content_modified":276},"NCT06892379","A Study of HS-20110 in Participants With Advanced Solid Tumors",[20],"2026-05-05T02:43:29.710102Z",{"nct_id":278,"title":279,"phases":280,"status":13,"updated_at":281,"content_modified":282},"NCT03486873","Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587\u002FKEYNOTE-587)",[107],"2026-08-26T02:19:24.527214Z","2026-05-05T02:43:29.706280Z",{"nct_id":284,"title":285,"phases":286,"status":13,"updated_at":287,"content_modified":288},"NCT06859762","A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors",[20],"2026-08-26T02:19:19.975067Z","2026-05-05T02:43:29.704387Z",{"nct_id":290,"title":291,"phases":292,"status":13,"updated_at":293,"content_modified":294},"NCT06635785","Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors",[12],"2026-08-26T02:15:11.740957Z","2026-05-05T02:43:29.698183Z",{"nct_id":296,"title":297,"phases":298,"status":13,"updated_at":299,"content_modified":300},"NCT05753722","A First-in-human Study of PRTH-101 Monotherapy +\u002F- Pembrolizumab in Subjects With Advanced Malignancies",[20],"2026-08-26T02:18:46.137046Z","2026-05-05T02:43:29.691661Z",{"nct_id":302,"title":303,"phases":304,"status":13,"updated_at":305,"content_modified":306},"NCT04617522","Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment",[20],"2026-08-26T02:15:46.655893Z","2026-05-05T02:43:29.682698Z",{"nct_id":308,"title":309,"phases":310,"status":13,"updated_at":311,"content_modified":312},"NCT05761223","A Phase I\u002FII, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849",[12],"2026-08-26T02:16:16.995720Z","2026-05-05T02:43:29.677136Z",[314,318,322,326,330,334,338,342,346,350,354,358,361,364,368,371,375,378,381,384,387,390,393,396],{"biomarker":315,"count":316,"slug":317},"GTPase KRas",49,"gtpase-kras",{"biomarker":319,"count":320,"slug":321},"MSI1 Gene",33,"msi1-gene",{"biomarker":323,"count":324,"slug":325},"ERBB2 Gene",28,"erbb2-gene",{"biomarker":327,"count":328,"slug":329},"Programmed Cell Death 1 Ligand 1",27,"programmed-cell-death-1-ligand-1",{"biomarker":331,"count":332,"slug":333},"MRC1 wt Allele",22,"mrc1-wt-allele",{"biomarker":335,"count":336,"slug":337},"Soluble Epidermal Growth Factor Receptor",18,"soluble-epidermal-growth-factor-receptor",{"biomarker":339,"count":340,"slug":341},"MTAP Gene",16,"mtap-gene",{"biomarker":343,"count":344,"slug":345},"BRAF Gene",15,"braf-gene",{"biomarker":347,"count":348,"slug":349},"RAS Family Oncogene",12,"ras-family-oncogene",{"biomarker":351,"count":352,"slug":353},"BRCA1 Gene",10,"brca1-gene",{"biomarker":355,"count":356,"slug":357},"G1\u002FS-Specific Cyclin-E1",9,"g1-s-specific-cyclin-e1",{"biomarker":359,"count":356,"slug":360},"PIK3CA Gene","pik3ca-gene",{"biomarker":362,"count":356,"slug":363},"ROS1 Gene","ros1-gene",{"biomarker":365,"count":366,"slug":367},"BRCA2 Gene",8,"brca2-gene",{"biomarker":369,"count":366,"slug":370},"NRAS Gene","nras-gene",{"biomarker":372,"count":373,"slug":374},"ALK Gene",7,"alk-gene",{"biomarker":376,"count":373,"slug":377},"AT-Rich Interactive Domain-Containing Protein 1A","at-rich-interactive-domain-containing-protein-1a",{"biomarker":379,"count":373,"slug":380},"CD276 wt Allele","cd276-wt-allele",{"biomarker":382,"count":373,"slug":383},"HLA-A Gene","hla-a-gene",{"biomarker":385,"count":373,"slug":386},"HLA Class I Histocompatibility Antigen, A-0201 Alpha Chain","hla-class-i-histocompatibility-antigen-a-0201-alpha-chain",{"biomarker":388,"count":373,"slug":389},"MET Gene","met-gene",{"biomarker":391,"count":373,"slug":392},"Partner and Localizer of BRCA2","partner-and-localizer-of-brca2",{"biomarker":394,"count":373,"slug":395},"Prolyl Endopeptidase FAP","prolyl-endopeptidase-fap",{"biomarker":397,"count":373,"slug":398},"TP53 Gene","tp53-gene",[400,404,408,412,416,420,424,428,432,436,440,444,448,452,456,460,464,468,472,476,479,483,487,491],{"state":401,"count":402,"slug":403},"Texas",590,"texas",{"state":405,"count":406,"slug":407},"California",452,"california",{"state":409,"count":410,"slug":411},"New York",371,"new-york",{"state":413,"count":414,"slug":415},"Florida",331,"florida",{"state":417,"count":418,"slug":419},"Tennessee",275,"tennessee",{"state":421,"count":422,"slug":423},"Virginia",244,"virginia",{"state":425,"count":426,"slug":427},"Michigan",238,"michigan",{"state":429,"count":430,"slug":431},"Massachusetts",233,"massachusetts",{"state":433,"count":434,"slug":435},"Ohio",227,"ohio",{"state":437,"count":438,"slug":439},"Pennsylvania",213,"pennsylvania",{"state":441,"count":442,"slug":443},"Colorado",171,"colorado",{"state":445,"count":446,"slug":447},"North Carolina",152,"north-carolina",{"state":449,"count":450,"slug":451},"New Jersey",147,"new-jersey",{"state":453,"count":454,"slug":455},"Illinois",143,"illinois",{"state":457,"count":458,"slug":459},"Washington",141,"washington",{"state":461,"count":462,"slug":463},"Missouri",139,"missouri",{"state":465,"count":466,"slug":467},"Arizona",138,"arizona",{"state":469,"count":470,"slug":471},"Connecticut",134,"connecticut",{"state":473,"count":474,"slug":475},"Maryland",132,"maryland",{"state":477,"count":474,"slug":478},"Minnesota","minnesota",{"state":480,"count":481,"slug":482},"Utah",124,"utah",{"state":484,"count":485,"slug":486},"Georgia",93,"georgia",{"state":488,"count":489,"slug":490},"Oregon",79,"oregon",{"state":492,"count":493,"slug":494},"Wisconsin",75,"wisconsin"]